 |
市場調查報告書
商品編碼
2075941
肝細胞癌治療市場：依藥物類別、治療方法、給藥途徑及地區分類。Hepatocellular Carcinoma Drugs Market, By Drug Class, By Treatment Modality, By Route of Administration, By Geography |
||||||
價格
簡介目錄
預計到 2026 年，肝細胞癌 (HMCC) 藥物市場規模將達到 73.6 億美元，到 2033 年將達到 128.7 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 8.3%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 73.6億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 8.30% | 2033年市場規模預測： | 128.7億美元 |
全球肝細胞癌 (HMCC) 治療市場涵蓋標靶治療、免疫療法、化療及類似藥物類別。這些療法廣泛用於第一線、第二線和輔助性治療，給藥途徑包括口服和靜脈注射。隨著各機構日益重視療效、效率和成本效益，這些領域的應用也穩定成長。
市場動態：
對口服和靜脈注射給藥的需求不斷成長、對提高療效和可靠性的需求以及持續的產品創新，預計將是推動全球肝細胞癌（HMC）治療市場成長的主要因素。一線和二線療法的廣泛應用進一步加速了這一成長勢頭。
例如，市場新進業者正在部署專為第一線治療應用場景設計的先進解決方案。此外，預計持續的技術進步和策略投資將在整個預測期內為市場新進入者創造新的成長機會。
本研究的主要特點：
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據公司概況、產品系列、主要亮點、財務表現和策略等參數，介紹了全球肝細胞癌 (HMC) 治療市場主要公司的概況。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 這份「全球肝細胞癌治療市場」報告的目標受群眾外包括產業內的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過利用分析全球肝細胞癌 (HMC) 藥物市場中使用的各種策略矩陣來簡化決策過程。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場概覽
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 近期產品發布
- 流行病學
- 併購和合作
- 監管趨勢
- 主要進展
- PEST分析
- 夥伴關係方案
- 品牌和定價分析
- 銷售代理情況
- 波特的分析
- 技術進步
- 主要進展
- 市場趨勢
- 前景
- 按銷售收入排名的主要公司
第4章 肝細胞癌治療市場：依藥物類別分類，2026-2033年
- 標靶治療
- 免疫療法
- 化療
- 聯合治療
- 其他
第5章 肝細胞癌治療市場：依治療方法分類，2026-2033年
- 一線治療
- 二級治療
- 輔助性治療
- 支持性護理
- 其他
第6章 肝細胞癌治療市場：依給藥途徑分類，2026-2033年
- 口服
- 靜脈
- 皮下
- 其他
第7章 肝細胞癌治療市場：依地區分類，2026-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 比荷盧經濟聯盟
- 丹麥
- 挪威
- 瑞典
- 其他歐洲國家
- 亞太地區
- 中國
- 台灣
- 印度
- 日本
- 印尼
- 馬來西亞
- 菲律賓
- 新加坡
- 澳洲
- 韓國
- 其他亞太國家
- 中東和非洲
- 巴林
- 科威特
- 阿曼
- 卡達
- 沙烏地阿拉伯
- UAE
- 以色列
- 南非
- 北非
- 中非
- 其他中東國家
第1章 競爭情勢
- Bayer AG
- Bristol-Myers Squibb
- Eisai Co., Ltd.
- F. Hoffmann-La Roche AG
- Novartis AG
- Pfizer Inc.
- AstraZeneca PLC
- Merck & Co., Inc.
- Ipsen SA
- Sanofi SA
- Johnson & Johnson
- Taiho Pharmaceutical Co., Ltd.
- Exelixis, Inc.
第2章
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI1596
Hepatocellular Carcinoma Drugs Market is estimated to be valued at USD 7.36 billion in 2026 and is expected to reach USD 12.87 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 7.36 billion |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.30% | 2033 Value Projection: | USD 12.87 billion |
The global hepatocellular carcinoma drugs market includes offerings that span Targeted Therapies, Immunotherapy, and Chemotherapy, and similar drug class categories. These are applied across First-line Treatment, Second-line Treatment, and Adjuvant Therapy and adopted by Oral, and Intravenous. As organizations increasingly prioritize performance, efficiency, and cost-effectiveness, adoption across these segments continues to grow steadily.
Market Dynamics:
Increasing demand from Oral, and Intravenous, the need for improved efficiency and reliability, and ongoing product innovation are major factors expected to drive growth of the global hepatocellular carcinoma drugs market. Broader adoption across First-line Treatment, and Second-line Treatment is reinforcing this momentum.
For instance, market players are introducing advanced solutions designed for First-line Treatment use cases. Moreover, continued technological advancement and strategic investment are expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global hepatocellular carcinoma drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Bayer AG, Bristol-Myers Squibb, Eisai Co, Ltd., F. Hoffmann-La Roche AG, Novartis AG, Pfizer Inc., Merck & Co, Inc., AstraZeneca PLC, Sanofi S.A., Johnson & Johnson, Taiho Pharmaceutical Co, Ltd., Exelixis, Inc., and Ipsen S.A, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global hepatocellular carcinoma drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hepatocellular carcinoma drugs market.
Detailed Segmentation:
- Global Hepatocellular Carcinoma Drugs Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
- Targeted Therapies
- Immunotherapy
- Chemotherapy
- Combination Therapy
- Others
- Global Hepatocellular Carcinoma Drugs Market, By Treatment Modality (Revenue, USD Bn, 2021 - 2033)
- First-line Treatment
- Second-line Treatment
- Adjuvant Therapy
- Supportive Care
- Others
- Global Hepatocellular Carcinoma Drugs Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Oral
- Intravenous
- Subcutaneous
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Bayer AG*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Bristol-Myers Squibb
- Eisai Co, Ltd.
- F. Hoffmann-La Roche AG
- Novartis AG
- Pfizer Inc.
- Merck & Co, Inc.
- AstraZeneca PLC
- Sanofi S.A.
- Johnson & Johnson
- Taiho Pharmaceutical Co, Ltd.
- Exelixis, Inc.
- Ipsen S.A
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Treatment Modality
- Market Snapshot, By Route of Administration
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Future Prospective
- Top Market Players by Revenue
4. Hepatocellular Carcinoma Drugs Market By Drug Class, 2026-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Targeted Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Combination Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
5. Hepatocellular Carcinoma Drugs Market By Treatment Modality, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- First Line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Second Line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Adjuvant Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Supportive Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
6. Hepatocellular Carcinoma Drugs Market By Route of Administration, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
7. Hepatocellular Carcinoma Drugs Market By Region, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Benelux
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- China
- Taiwan
- India
- Japan
- Indonesia
- Malaysia
- Philippines
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Bahrain
- Kuwait
- Oman
- Qatar
- Saudi Arabia
- UAE
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
1. Competitive Landscape
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ipsen S.A
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Taiho Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Exelixis, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
2. Section
- Research Methodology
- About Us
